Pegloticase and Chronic Gout

被引：4
|
作者：
Ea, Hang-Korng [1 ]
Chales, Gerard [2 ]
Liote, Frederic [1 ]
机构：
[1] Univ Paris Diderot, Paris, France
[2] Univ Rennes, Rennes, France
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2011年 / 306卷 / 18期
关键词：
D O I：
10.1001/jama.2011.1616
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1979 / 1979
页数：1
相关论文
共 50 条
  • [41] Gout Treatment and Clinical Considerations: The Role of Pegloticase, Colchicine, and Febuxostat
    Quintana, Michael J.
    Shum, Alika Z.
    Folse, Michael S.
    Ramesh, Prerana C.
    Ahmadzadeh, Shahab
    Varrassi, Giustino
    Shekoohi, Sahar
    Kaye, Alan D.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (10)
  • [42] Impact of pegloticase on patient outcomes in refractory gout: current perspectives
    Cunha, Rita N.
    Aguiar, Renata
    Farinha, Filipa
    OPEN ACCESS RHEUMATOLOGY-RESEARCH AND REVIEWS, 2018, 10 : 141 - 149
  • [43] A Case Report of Successful Management of Refractory Polyarticular Gout With Pegloticase
    Alnabwani, Dina
    Prasad, Ankita
    Raslan, Ashraf
    Cheriyath, Pramil
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (08)
  • [44] Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase
    Brian F. Mandell
    Anthony E. Yeo
    Peter E. Lipsky
    Arthritis Research & Therapy, 20
  • [45] Characterization of patients with chronic refractory gout who do and do not have clinically apparent tophi and their response to pegloticase
    Edwards, N. Lawrence
    Singh, Jasvinder A.
    Troum, Orrin
    Yeo, Anthony E.
    Lipsky, Peter E.
    RHEUMATOLOGY, 2019, 58 (08) : 1422 - 1431
  • [46] PEGLOTICASE FOR REFRACTORY GOUT: EFFICACY AND SAFETY SUMMARY OF THE GOUT1 AND GOUT2 PHASE III TRIALS
    Sundy, John S.
    Baraf, Herbert S.
    Becker, Michael
    Treadwell, Edward L.
    Yood, Robert
    Ottery, Faith D.
    RHEUMATOLOGY, 2013, 52 : 43 - 43
  • [47] Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase
    Mandell, Brian F.
    Yeo, Anthony E.
    Lipsky, Peter E.
    ARTHRITIS RESEARCH & THERAPY, 2018, 20
  • [48] CHARACTERIZATION OF PATIENTS WITH CHRONIC REFRACTORY GOUT WHO DO AND DO NOT HAVE CLINICALLY APPARENT TOPHI: RESPONSE TO PEGLOTICASE
    Edwards, N. L.
    Singh, J.
    Troum, O.
    Yeo, A.
    Lipsky, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 377 - 377
  • [49] TREATMENT WITH PEGLOTICASE IMPROVES HEPATIC FIBROSIS ESTIMATED BY FIBROSIS-4 INDEX IN SUBJECTS WITH CHRONIC REFRACTORY GOUT
    Schlesinger, N.
    Yeo, A.
    Lipsky, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 450 - 450
  • [50] PHARMACOKINETICS OF PEGLOTICASE AND METHOTREXATE POLYGLUTAMATE(S) IN PATIENTS WITH UNCONTROLLED GOUT RECEIVING PEGLOTICASE AND CO-TREATMENT OF METHOTREXATE
    Song, Y.
    Xin, Y.
    Weinblatt, M. E.
    Chamberlain, J.
    Obermeyer, K.
    Zhao, L.
    Canavan, C.
    Peloso, P. M.
    Ramanathan, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 847 - 848
12345